Tomigusuku

Researchers are evaluating the safety and effectiveness of surgical aortic valve replacement (SAVR) compared to transcatheter aortic valve replacement (TAVR) in patients with isolated severe, calcific aortic stenosis who are at low surgical risk. This prospective, randomized, controlled, multi-center study aims to determine if SAVR is not inferior to TAVR in terms of death from any cause, stroke, and rehospitalization related to valve procedures within one year after surgery. Participants will be randomly assigned to receive either SAVR or TAVR using commercially available surgical and transcatheter bioprosthetic valves. The study includes follow-up visits at hospital discharge, 30 days after the procedure, and then annually for up to 10 years to monitor outcomes and safety. Both procedures involve valve replacement but differ in their surgical approach. During the study, participants will undergo assessments to track mortality, stroke events, and hospital readmissions related to valve or procedure complications. Researchers will collect clinical data and monitor participants regularly over the long-term follow-up period to evaluate the combined primary endpoint at one year post-procedure and observe ongoing safety and effectiveness.

Researchers are evaluating an experimental drug called REGN7508, a Factor XI monoclonal antibody, to prevent Venous Thromboembolism (VTE) after elective, unilateral total knee replacement surgery in adults. The study is a Phase 3, multicenter, randomized, open-label trial comparing REGN7508 with Apixaban and Enoxaparin, two other blood-thinning medications, as well as a placebo. The goal is to assess how well REGN7508 works to stop VTE and related conditions following knee surgery, along with monitoring possible side effects, drug levels in the blood, and the body's immune response to the drug.